Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3272 - First-In-Human Phase I Study of PF-06747775, a Third Generation Mutant Selective EGFR Tyrosine Kinase Inhibitor (TKI) in Metastatic EGFR Mutant NSCLC after Progression on a First-Line EGFR TKI


09 Sep 2017


Poster display session


Hatim Husain


Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380


H. Husain1, R.G. Martins2, S.B. Goldberg3, P. Senico4, W. Ma5, J. Masters6, N. Pathan6, D. Kim7, M.A. Socinski8, Z. Goldberg5, B.C. Cho9

Author affiliations

  • 1 Medicine, UC San Diego Moores Cancer Center, 92093 - San Diego/US
  • 2 Oncology/hematology, Seattle Cancer Care Alliance, Seattle/US
  • 3 Medical Oncology, Yale Cancer Center, New Haven/US
  • 4 Oncology, Pfizer, Collegeville/US
  • 5 Oncology, Pfizer, New York/US
  • 6 Oncology, Pfizer, La Jolla/US
  • 7 Oncology, Seoul National University Hospital, Seoul/KR
  • 8 Oncology, University of Pittsburgh, Pittsburgh/US
  • 9 Oncology, Yonsei Cancer Center, Yonsei/KR


Abstract 3272


PF-06747775 (“PF-7775”) is a selective, 3rd generation Epidermal Growth Factor Receptor (EGFR) TKI effective against EGFR sensitizing and T790M mutations in preclinical models. Enrollment was completed in a phase I study of PF-7775 in EGFR mutant (EGFRm+) NSCLC patients (pts) who progressed after a prior EGFR TKI.


EGFRm+ NSCLC pts with resistance to first-line EGFR-TKIs enrolled in a multicenter trial in 6 dose escalation (25 mg–600 mg) and 2 dose expansion cohorts (200 mg and 300 mg). Biopsy for EGFR T790M at clinical progression was not required for study entry. PF-7775 was given orally once daily. All pts were assessed for response, adverse events (AEs), and pharmacokinetics. Plasma T790M testing was conducted retrospectively.


As of a 3 Feb17 data cutoff, 44 pts were enrolled (59% female, median age 63.5, Asian/Caucasian 73/25%).The most common all grade AEs in all enrolled patients (≥ 25%) were: diarrhea (57%), rash (59%), paronychia (52%), dermatitis acneiform (34%), stomatitis (32%), pruritus (27%), dry skin (25%), and rhinorrhea (25%). Grade 3 events were consistent with known EGFR TKI toxicities (diarrhea and skin toxicity) and easily managed. No grade 4 treatment related AEs were noted in dose escalation or expansion. Nineteen pts (43%) had dose reductions due to treatment related AEs at the higher dose cohorts and the RP2D of 200 mg was selected based on the AE profile and tolerability of drug at this dose for longer term administration. The prevalence rate of T790M, L858R, and del 19 in plasma samples, along with data correlating ORR (CR and PR rate) and CBR (CR + PR + SD) is ongoing.


PF-7775 is well tolerated at 200 mg dose in EGFRm+ NSCLC pts with acquired resistance to first-line EGFR-TKIs. Data relating mutational status to response rate in plasma is ongoing.

Clinical trial identification


Legal entity responsible for the study

Pfizer Inc.


Pfizer Inc.


P. Senico, W. Ma, J. Masters, N. Pathan, Z. Goldberg: Employee of Pfizer and declare Pfizer stock ownership. B.C. Cho: Conducting Pfizer corporate-sponsored research. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.